Victory Capital Management Inc Halozyme Therapeutics, Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

A detailed history of Victory Capital Management Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 406,811 shares of HALO stock, worth $23.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

406,811

Previous 244,477 66.4%

Holding current value

$23.1 Million

Previous $12.8 Million 81.82%

% of portfolio

0.02%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$51.3 - $64.42 $8.33 Million - $10.5 Million	162,334 Added 66.4%	406,811 $23.3 Million
Q2 2024 Aug 05, 2024	SELL	$37.81 - $52.4 $921,429 - $1.28 Million	-24,370 Reduced 9.06%	244,477 $12.8 Million
Q1 2024 May 03, 2024	SELL	$33.68 - $41.95 $273,414 - $340,550	-8,118 Reduced 2.93%	268,847 $10.9 Million
Q4 2023 Feb 05, 2024	SELL	$33.32 - $42.1 $91,663 - $115,817	-2,751 Reduced 0.98%	276,965 $10.2 Million
Q3 2023 Nov 06, 2023	BUY	$36.46 - $44.03 $533,227 - $643,938	14,625 Added 5.52%	279,716 $10.7 Million
Q2 2023 Jul 27, 2023	BUY	$30.28 - $38.74 $729,142 - $932,859	24,080 Added 9.99%	265,091 $9.56 Million
Q1 2023 May 02, 2023	SELL	$32.86 - $55.7 $38.6 Million - $65.4 Million	-1,174,345 Reduced 82.97%	241,011 $9.2 Million
Q4 2022 Feb 10, 2023	SELL	$40.06 - $59.44 $50,635 - $75,132	-1,264 Reduced 0.09%	1,415,356 $80.5 Million
Q4 2022 Feb 09, 2023	BUY	$40.06 - $59.44 $8.85 Million - $13.1 Million	220,934 Added 18.48%	1,416,620 $80.6 Million
Q3 2022 Nov 02, 2022	SELL	$38.53 - $51.78 $22.9 Million - $30.8 Million	-594,358 Reduced 33.2%	1,195,686 $47.3 Million
Q2 2022 Aug 01, 2022	BUY	$37.35 - $48.3 $45.1 Million - $58.3 Million	1,206,368 Added 206.68%	1,790,044 $78.8 Million
Q1 2022 May 04, 2022	SELL	$31.97 - $41.06 $8.97 Million - $11.5 Million	-280,497 Reduced 32.46%	583,676 $23.3 Million
Q4 2021 Feb 07, 2022	SELL	$31.82 - $40.75 $1.81 Million - $2.32 Million	-56,828 Reduced 6.17%	864,173 $34.7 Million
Q3 2021 Nov 02, 2021	BUY	$38.47 - $46.42 $1.19 Million - $1.44 Million	30,932 Added 3.48%	921,001 $37.5 Million
Q2 2021 Aug 03, 2021	SELL	$38.84 - $51.31 $7.78 Million - $10.3 Million	-200,329 Reduced 18.37%	890,069 $40.4 Million
Q1 2021 May 04, 2021	SELL	$39.51 - $51.45 $213,077 - $277,469	-5,393 Reduced 0.49%	1,090,398 $45.5 Million
Q4 2020 Feb 01, 2021	SELL	$25.81 - $43.62 $9.88 Million - $16.7 Million	-382,879 Reduced 25.89%	1,095,791 $46.8 Million
Q3 2020 Nov 09, 2020	SELL	$25.74 - $29.63 $1.5 Million - $1.72 Million	-58,137 Reduced 3.78%	1,478,670 $38.9 Million
Q2 2020 Aug 07, 2020	BUY	$16.25 - $26.81 $19.9 Million - $32.9 Million	1,226,356 Added 395.02%	1,536,807 $41.2 Million
Q1 2020 May 04, 2020	BUY	$13.9 - $21.83 $3.67 Million - $5.76 Million	263,895 Added 566.83%	310,451 $5.59 Million
Q4 2019 Feb 06, 2020	BUY	$14.93 - $19.53 $109,914 - $143,779	7,362 Added 18.78%	46,556 $825,000
Q4 2019 Feb 04, 2020	SELL	$14.93 - $19.53 $16,766 - $21,932	-1,123 Reduced 2.79%	39,194 $744,000
Q3 2019 Nov 12, 2019	BUY	$15.2 - $17.69 $612,818 - $713,207	40,317 New	40,317 $625,000
Q2 2019 Aug 15, 2019	SELL	$14.75 - $17.26 $1.65 Million - $1.93 Million	-111,610 Closed	0 $0
Q1 2019 May 03, 2019	SELL	$13.94 - $17.58 $112,356 - $141,694	-8,060 Reduced 6.74%	111,610 $1.8 Million
Q4 2018 Feb 05, 2019	SELL	$13.33 - $18.66 $28,259 - $39,559	-2,120 Reduced 1.74%	119,670 $1.75 Million
Q3 2018 Nov 01, 2018	SELL	$16.68 - $18.41 $107,752 - $118,928	-6,460 Reduced 5.04%	121,790 $2.21 Million
Q2 2018 Aug 02, 2018	SELL	$16.87 - $20.3 $119,945 - $144,333	-7,110 Reduced 5.25%	128,250 $2.16 Million
Q1 2018 May 04, 2018	BUY	$17.06 - $21.2 $2.31 Million - $2.87 Million	135,360 New	135,360 $2.65 Million

Others Institutions Holding HALO

# of Institutions

534

Shares Held

123M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.91B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Halozyme Therapeutics, Inc. Transaction History